Published in Cancer Weekly, February 8th, 2005
"The submission of this New Drug Application is an important milestone in Abbott's commitment to prostate cancer patients and their families," said John Leonard, MD, vice president, Global Pharmaceutical Development at Abbott. "Our novel pipeline for drug development has the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.